DDInter1607 DDInter1376
Ritonavir is an HIV protease inhibitor that interferes with the reproductive cycle of HIV. Although it was initially developed as an independent antiviral agent, it has been shown to possess advantageous properties in combination regimens with low-dose ritonavir and other protease inhibitors. It is now more commonly used as a booster of other protease inhibitors and is available in both liquid formulations and as capsules. While ritonavir is not an active antiviral agent against hepatitis C virus (HCV) infection, it is added in combination therapies indicated for the treatment of HCV infections as a booster. Ritonavir is a potent CYP3A inhibitor that increases peak and trough plasma drug concentrations of other protease inhibitors such as and overall drug exposure. American Association for the Study of Liver Diseases (AASLD) and the Infectious Diseases Society of America (IDSA) guidelines recommend ritonavir-boosted combination therapies as first-line therapy for HCV Genotype 1a/b and
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approved by the FDA on March 26, 2020.[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.[L39377,L39382] MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting. In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular [interferon beta-1a], a current standard in MS therapy. Studies involving patients with inflammatory bowel disease have also shown promising results.[A189318,A189342]
Ritonavir {u} (Compound) resembles {v} (Compound) Atazanavir
Ritonavir {u} (Compound) resembles {v} (Compound) Lopinavir
Ritonavir {u} (Compound) treats {v} (Disease) acquired immunodeficiency syndrome
Ritonavir {u} (Compound) binds {v} (Gene) SLCO1A2
Ritonavir {u} (Compound) upregulates {v} (Gene) AGR2
Ritonavir {u} (Compound) is included by {v} (Pharmacologic Class) Breast Cancer Resistance Protein Inhibitors
Ritonavir {u} (Compound) downregulates {v} (Gene) NT5DC2
Ritonavir {u} (Compound) causes {v} (Side Effect) Blood triglycerides increased
Ritonavir (Compound) resembles Atazanavir (Compound)
Ritonavir (Compound) resembles Lopinavir (Compound)
Ritonavir (Compound) treats acquired immunodeficiency syndrome (Disease)
Ritonavir (Compound) binds SLCO1A2 (Gene)
Ritonavir (Compound) upregulates AGR2 (Gene)
Ritonavir (Compound) is included by Breast Cancer Resistance Protein Inhibitors (Pharmacologic Class)
Ritonavir (Compound) downregulates NT5DC2 (Gene)
Ritonavir (Compound) causes Blood triglycerides increased (Side Effect)